|Table of Contents|

Expression of β-catenin,STT3A and PD-L1 in gastric cancer and correlation with pathological festures and prognosis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 07
Page:
1270-1275
Research Field:
Publishing date:

Info

Title:
Expression of β-catenin,STT3A and PD-L1 in gastric cancer and correlation with pathological festures and prognosis
Author(s):
WU Xueyu1; HU Nan1; ZHOU Kangjie2; LAI Huan1; WU Fenglei1
1.The Affiliated Lianyungang Hospital of Xuzhou Medical University,Jiangsu Lianyungang 222000,China;2.Lianyungang Clinical College of Nanjing Medical University,Jiangsu Lianyungang 222000,China.
Keywords:
gastric cancer; post-translational modifications; glycosylation; β-catenin; STT3A; PD-L1
PACS:
R735.2
DOI:
10.3969/j.issn.1672-4992.2023.07.017
Abstract:
Objective:To investigate the expression of β-catenin,STT3A and PD-L1 related proteins in gastric cancer and their correlation with pathological features and prognosis.Methods:The expression of β-catenin,STT3A and PD-L1 related proteins in gastric cancer and adjacent tissues were detected by immunohistochemistry from 63 cases of gastric cancer tissues and adjacent tissues from February 2020 to October 2021,and the relationship between the expression and clinicopathological parameters was investigated.The correlation among β-catenin,STT3A and PD-L1 was analyzed.The expressions of β-catenin,STT3A and PD-L1 proteins in gastric cancer cells were detected by Western blot.The possible influencing factors of glycosylation modification of stable PD-L1 expression were explored,to provide a new idea for immune checkpoint inhibitor therapy of gastric cancer.Results:The positive expression rates of β-catenin and STT3A in gastric cancer tissues were higher than those in adjacent tissues(P<0.05),which were related to tumor differentiation,tumor diameter,lymph node metastasis and clinical TNM stage(P<0.05),but had no significant correlation with age and gender(P>0.05).The positive expression rate of PD-L1 in gastric cancer tissues was higher than that in adjacent tissues(P<0.05),which was related to the degree of tumor differentiation and clinical TNM stage(P<0.05),but had no significant correlation with age,gender,tumor diameter and lymph node metastasis(P>0.05).In gastric cancer tissues,β-catenin was positively correlated with the expression of STT3A and PD-L1(P<0.05),and PD-L1 was positively correlated with the expression of STT3A(P<0.05).Conclusion:The expression levels of β-catenin,STT3A and PD-L1 proteins in gastric cancer are higher than those in the paracancer,and are related to the degree of tumor differentiation and clinical TNM stage,so the three proteins may be related to the prognosis of tumor.In addition,the expressions of β-catenin,STT3A and PD-L1 were correlated.The results indicated that β-catenin may regulate STT3A and thus regulate the glycosylation process of PD-L1 in gastric cancer tissues,thus affecting the stable expression of PD-L1.

References:

[1] MACHLOWSKA J,BAJ J,SITARZ M,et al.Gastric cancer:Epidemiology,risk factors,classification,genomic characteristics and treatment strategies ［J］.Int J Mol Sci,2020,21(11):4012.
[2] JOSHI SS,BADGWELL BD.Current treatment and recent progress in gastric cancer ［J］.CA Cancer J Clin,2021,71(3):264-279.
[3] XIE F,XU M,LU J,et al.The role of exosomal PD-L1 in tumor progression and immunotherapy ［J］.Mol Cancer,2019,18(1):146.
[4] LIU J,LI H,SUN L,et al.Profiles of PD-1,PD-L1,PD-L2 in gastric cancer and their relation with mutation,immune infiltration and survival ［J］.Biomed Res Int,2020,2020:2496582.
[5] FUCHS CS,DOI T,JANG RW,et al.Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer:Phase 2 clinical KEYNOTE-059 trial ［J］.JAMA Oncol,2018,4(5):e180013.
[6] XIE T,ZHANG Z,ZHANG X,et al.Appropriate PD-L1 cutoff value for gastric cancer immunotherapy:A systematic review and Meta-analysis ［J］.Front Oncol,2021,11:646355.
[7] 崔宇琦,邹朝霞,高旭.免疫检查点程序性细胞死亡蛋白配体-1翻译后修饰及其在免疫治疗中的应用前景［J］.中国生物化学与分子生物学报,2021,37(02):182-188. CUI YQ,ZOU ZX,GAO X.Posttranslational modification of programmed cell death ligand-1 at the immune checkpoint and its potential application in immunotherapy ［J］.Chinese Journal of Biochemistry and Molecular Biology,2021:37(02):182-188.
[8] 黄天宇,陈勇.PD-L1 蛋白N端糖基化修饰在免疫治疗研究中的进展［J］.肿瘤,2020,40（9）：650-655. HUANG TY,CHEN Y.Advances in immunotherapy of N-terminal glycosylation of PD-L1 protein［J］.Tumour,2020,40（9）：650-655.
[9] HSU JM,XIA W,HSU YH,et al.STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion ［J］.Nat Commun,2018,9(1):1908.
[10] WANG YN,LEE HH,HSU JL,et al.The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis ［J］.J Biomed Sci,2020,27(1):77.
[11] RUAN Z,LIANG M,LAI M,et al.KYA1797K down-regulates PD-L1 in colon cancer stem cells to block immune evasion by suppressing the beta-catenin/STT3 signaling pathway ［J］.Int Immunopharmacol,2020,78:106003.
[12] 李腊秀,王科,赵家宁,等.胃癌组织中 SOX1 与β-catenin 的表达及其与病理特征、远期预后的相关性 ［J］.中国现代医学杂志,2021,31(13):30-34. LI LX,WANG K,ZHAO JN,et al.Expression of SOX1 and β-catenin in gastric cancer and its correlation with clinicopathological features and long-term prognosis［J］.Chinese Journal of Modern Medicine,2021,31(13):30-34.
[13] SHANG S,HUA F,HU ZW.The regulation of β-catenin activity and function in cancer［J］.Oncotarget,2017,8(20):33972-33989.
[14] MA XM,LUO YF,ZENG FF,et al.TGF-beta1-mediated PD-L1 glycosylation contributes to immune escape via c-Jun/STT3A pathway in nasopharyngeal carcinoma ［J］.Front Oncol,2022,12:815437.
[15] CHAN LC,LI CW,XIA W,et al.IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion ［J］.J Clin Invest,2019,129(8):3324-3338.
[16] LIAO C,AN J,TAN Z,et al.Changes in protein glycosylation in head and neck squamous cell carcinoma ［J］.J Cancer,2021,12(5):1455-1466.
[17] VERDURA SCE,CORTADA E,BRUNET J,et al.Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity6［J］.Aging(Albany NY),2020,12(1):8-34.
[18] HU L, LIN ZX,WANG ZW.Emerging role of PD-L1 modification in cancer immunotherapy［J］.Am J Cancer Res,2021:11(8):3832-3840.
[19] LI CW,LIM SO,XIA W,et al.Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity ［J］.Nat Commun,2016,7:12632.
[20] 李胤,陈一苇,陈芳华,等.PD-1/PD-L1的糖基化修饰对肿瘤免疫治疗影响的研究进展［J］.复旦学报(医学版),2021,48(05):666-670. LI Y,CHEN YW,CHEN FH,et al.Research progress on the effect of glycosylation of PD-1/PD-L1 on tumor immunotherapy［J］.Journal of Fudan University(Medical Science),2021,48(05):666-670.
[21] LEE HH,WANG YN,XIA W,et al.Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1/PD-L1 therapeutic efficacy ［J］.Cancer Cell,2019,36(2):168-178.
[22] GU L,CHEN M,GUO D,et al.PD-L1 and gastric cancer prognosis:A systematic review and meta-analysis ［J］.PLoS One,2017,12(8):e0182692.
[23] 沈仕俊，甘平，王园园，等.PD-1/PD-L1通路抑制剂治疗进展期胃癌的研究进展［J］.现代肿瘤医学，2021，29（13）：2363-2368. SHEN SJ,GAN P,WANG YY,et al.Research progress of PD-1/PD-L1 pathway inhibitors in advanced gastric cancer［J］.Oncology Modern,2021，29（13）：2363-2368.

Memo

Memo:
National Natural Science Foundation of China（No.81802347）;国家自然科学基金青年科学基金项目（编号：81802347）；江苏省社会发展面上项目（编号：BE2019693）；吴阶平医学基金项目（编号：320.6750.19058）
Last Update: 2023-02-28